Our Remarkable Journey
We've consistently demonstrated our commitment to excellence by navigating through various audits conducted by regulatory authorities and customers globally, solidifying our growth and reputation in the field.
Our journey in the pharmaceutical industry has been defined by a succession of pivotal achievements.
KEY MILESTONES
1992
Alkaloids Private Limited was established.
1997
Alkaloids Private Limited developed its first Scopolamine/Hyoscine Salt.
2000
Alkaloids first Block in the manufacturing facility, was inaugurated.
2002
Alkaloids Private Limited received its first Certificate of Suitability (CEP) for Hyoscine Butylbromide.
2007
Block II, expanding Alkaloids manufacturing capacity, was inaugurated.
2009
Alkaloids Private Limited attained its first KMFDS accreditation.
2011
Alkaloids Private Limited completed its first USFDA audit, resulting in facility acceptance.
2013
Block III, Alkaloids largest manufacturing facility to date, wass inaugurated. Alkaloids also acquired its first piece of farmland in Australia for biomass.
2014
Alkaloids Private Limited established its Process Development Lab.
2015
Alkaloids Private Limited successfully cleared its first TGA Audit
2018
Alkaloids Private Limited completed its first EDQM audit.
2019
The Potent Molecule Handling Block was established in Block III.
What We Have Accomplished
Alkaloids milestones underscore its commitment to quality and compliance, as well as its unwavering dedication to pushing the boundaries of pharmaceutical innovation. Each achievement is a testament to the company's enduring pursuit of excellence.
31
Years in business
85
Countries Served
Get To Know More
About our products, send us a query or
download our catalog.